AUP1602-C

N/A

Report date: 2024/01/23 15:26:35

Base Information

Drug NameAUP1602-C
Drug Alias NameAUP-16AUP1602-C
ClassificationNatural product/Extract > Microbial extractBiologics > Live Biotherapeutic
Mechanisms of ActionBacteria replacementsFibroblast growth factor receptor 1 antagonistsInterleukin-4 inhibitors +[4] 
TargetsFibroblast growth factor receptor 1Interleukin-4Colony stimulating factor
Therapy Area/IndicationsUlcerDiabetic Foot
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPolandItalyGermany +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAurealis
China Registration ClassN/A

Develop Information

Active CompaniesAurealis OyShenzhen Xbiome Biotechnology Co LtdAurealis Therapeutics AG
Inactive CompaniesN/A
Active IndicationsUlcerDiabetic Foot
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A